Demonstration of in situ fibrin degradation in pathologic thrombi.
Fibrin prepared from 15 pathologic thrombi was examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to determine the extent and pattern of fibrinolysis that occurs in vivo. Two groups of patients could be distinguished on the basis of the polypeptide chain composition of fibrin in their thrombi. Those patients who presented with acute vascular obstruction, either arterial or venous, showed a minimal degree of fibrin degradation, with a dominance of intact, undegraded crosslinked gamma-gamma dimers. On the other hand, patients with long-standing symptoms associated with chronic aortic aneurysms had thrombi containing extensively degraded fibrin. Thrombi in large aortic aneurysms were dissected into concentric layers that showed different degrees of fibrinolysis. The luminal surface consisted of fresh, red thrombus and contained undegraded crosslinked fibrin similar to that found in patients with acute occlusive disease. Deeper layers of the thrombus showed gamma-gamma chain degradation throughout, indicating that this portion was undergoing active thrombolysis. The findings demonstrate that the variability in the pathophysiologic balance between coagulation and fibrinolysis is reflected in vivo by the polypeptide chain composition of crosslinked fibrin in thrombi. The results support the hypothesis of a dynamic equilibrium between clotting and lysis, but indicate that the balance between these two processes may be distinctly different in separate areas of a single clot.
D000328:Adult; D000368:Aged; D001012:Aorta, Abdominal; D001014:Aortic Aneurysm / Q000097:blood / Q000473:pathology / Q000503:physiopathology; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000473:pathology / Q000503:physiopathology; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005263:Femoral Artery; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D005341:Fibrinolysin / Q000502:physiology; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects; D013927:Thrombosis / Q000097:blood* / Q000473:pathology / Q000503:physiopathology
D005338:Fibrin Fibrinogen Degradation Products; D010455:Peptides; D005341:Fibrinolysin